What sacituzumab tirumotecan is
Sacituzumab tirumotecan (sac-TMT) is an antibody–drug conjugate (ADC). It is an antibody that recognizes TROP2, a protein found on the surface of many solid tumors, chemically linked to a potent chemotherapy payload. The antibody carries the payload to TROP2-bearing cancer cells, where it is released to kill them. The idea is to concentrate chemotherapy where it is needed.
Sac-TMT was originated by Sichuan Kelun-Biotech. Merck develops it under an exclusive license and collaboration agreement and, according to its SEC filings, retains decision-making authority over development and commercialization.
Clinical evidence: TroFuse-005
TroFuse-005 enrolled 776 patients with advanced or recurrent endometrial cancer whose disease had progressed after platinum-based chemotherapy and immunotherapy. They were randomized to sac-TMT or chemotherapy chosen by the physician. Results were published in The Lancet in October 2026:
| Measure | Sac-TMT | Physician's choice |
|---|---|---|
| Median progression-free survival | 7.2 months | 3.9 months |
| Progression-free survival hazard ratio | 0.59 | |
| Median overall survival | 19.0 months | 12.1 months |
| Overall survival hazard ratio | 0.68 | |
| Grade 3 or higher adverse events | 69% | 57% |
The overall survival benefit, a nearly seven-month improvement in median survival, is the strongest kind of evidence in oncology. Treatment-related deaths were rare and similar between groups (under 1% each).
Regulatory status
China: the National Medical Products Administration (NMPA) granted marketing authorization in November 2024 for adults with unresectable locally advanced or metastatic triple-negative breast cancer who had received at least two prior systemic therapies, at least one for advanced disease. Kelun-Biotech describes it as the first domestically developed ADC fully approved for marketing in China. By August 2026, Kelun reported four approved indications in China, covering previously treated triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and HR-positive, HER2-negative breast cancer, with more applications under review (company-reported).
United States: Merck reports that the FDA accepted its Biologics License Application for patients with endometrial cancer previously treated with platinum chemotherapy and a PD-1 or PD-L1 inhibitor, under priority review, with a target action date of June 15, 2027. The FDA had selected sac-TMT for a Commissioner's National Priority Voucher in December 2025. Merck has said it hopes for approval before the target date (company-reported). openFDA lists no approved application yet.
Scientific perspective
ADCs have become one of oncology's most productive drug classes, and TROP2 is one of their most contested targets. TroFuse-005 is notable because it showed an overall survival benefit in a randomized trial against active treatment, rather than relying on response rates or progression-free survival alone. The higher rate of serious side effects is typical of ADCs, which still deliver chemotherapy, and will be weighed against the survival gain.
Development perspective
- Next milestone: the FDA decision for endometrial cancer, due by June 15, 2027 (company-reported). Historically, about 90.6% of applications that reach the FDA are eventually approved. That is an industry-wide average, not a prediction.
- Breadth: the registry lists more than 100 trials, including several large Phase 3 studies in lung and breast cancer. Many are run in China, where Kelun leads development.
- Partnership: Merck's filings note a separate funding agreement with Blackstone for part of sac-TMT's development costs, which does not change Merck's control of the program.
Development timeline
- Jan 5, 2024TroFuse-005 begins randomizing patients with previously treated endometrial cancer. Peer-reviewed
- Nov 27, 2024Kelun-Biotech announces China NMPA marketing authorization for adults with unresectable locally advanced or metastatic triple-negative breast cancer after at least two prior systemic therapies. Company-reported
- Dec 2025FDA selects sac-TMT for a Commissioner's National Priority Voucher. Company-reported
- Aug 17, 2026Kelun-Biotech reports four approved indications in China: previously treated triple-negative breast cancer, EGFR-mutant lung cancer, and HR+/HER2- breast cancer. Company-reported
- Oct 26, 2026TroFuse-005 published: overall survival 19.0 vs 12.1 months (HR 0.68) and progression-free survival 7.2 vs 3.9 months (HR 0.59). Peer-reviewed
- Nov 4, 2026Merck reports its application is under FDA priority review for previously treated endometrial cancer, with a June 15, 2027 target date. Company-reported
What could change the outlook
- The FDA decision, due by June 15, 2027. Merck has said it hopes for approval before that date (company-reported).
- Phase 3 readouts in lung and breast cancer, which would determine whether sac-TMT becomes a broad oncology product.
- Safety: grade 3 or higher adverse events occurred in 69% of patients on sac-TMT in TroFuse-005, versus 57% on chemotherapy.
- Competition from other TROP2-directed antibody–drug conjugates.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Sacituzumab tirumotecan. Company-reported, not independently verified.
- Quarterly reportCompany-reportedOct 29, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
“The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline.
- RegulatoryCompany-reportedOct 27, 2026
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application ("the application") for its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱...
- Trial resultsCompany-reportedOct 25, 2026
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the prespecified final overall survival (OS) analysis results of the Phase III OptiTROP-Lung04 study of sacituzumab...